Coffee Consumption Associated with Lower Risk of Hepatocellular Carcinoma
the Cancer Therapy Advisor take:
A significant relationship has been found between coffee consumption and a reduced risk of developing hepatocellular carcinoma (HCC), but not with intrahepatic cholangiocarcinoma (ICC), according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included 1,212,893 participants (HCC: n = 860, ICC: n = 260) from the Liver Cancer Pooling Project.
Results showed that increased coffee consumption was associated with a reduced risk of HCC (HR > 3 cups/day vs. non-drinker, 0.73; 95% CI: 0.53, 0.99; Ptrend cups/day < 0.0001). Women who consumed more than three cups of coffee per day had a significantly more reduced risk of HCC (54%) compared to men (HR, 0.46; 95% CI: 0.26, 0.81 compared to HR, 0.93; 95% CI: 0.63, 1.37, respectively; Pinteraction = 0.07).
Caffeinated coffee (HR > 3 cups/day vs. non-drinker, 0.71; 95% CI: 0.50, 1.01) displayed a stronger association with decreased HCC risk than decaffeinated coffee (HR, 0.92; 95% CI: 0.55, 1.54).
The study suggests further evaluations be conducted on specific coffee compounds and mechanisms to better understand their association with reduced HCC risk.
A significant relationship has been found between coffee consumption and a reduced risk of developing HCC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Larotrectinib Continues to Show Efficacy in TRK-Fusion Cancers
- First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
- Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer
- Entrectinib Shrank NTRK Fusion-Positive Solid Tumors
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer